Skip to content
value.today
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc.

ALLO
$450 Mmarket cap on Oct 29, 2026-21.0% since Jan 2024
Compare
World rank
#13,047
Revenue
$0 M
For year ending December-2025
value.today research
Net income
$-191 M
value.today research
Employees
310
As on 2021
value.today research

Allogene Therapeutics, Inc. in brief

Allogene Therapeutics, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. It was founded in 2017. Its market value was $450 M on 29 October 2026, which makes it the 13,047th largest listed company in the world and the 2,599th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $191 M. It employs about 310 people and Zachary Roberts is its chief executive. Its largest business segments by sales in 2024 were Reportable (100%). Its shares trade under the symbol ALLO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Allogene Therapeutics, Inc.

Allogene Therapeutics is a Clinical Stage Biotechnology company. It single minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell therapies for cancer and researchers is dedicated to discovery and translational research, development and cell manufacturing. The headquarters is in USA.

Allogene Therapeutics, Inc. timeline

3 events, 2017–2018
  1. 2017
  2. 🏁
    · approximate
    Founded
  3. 2018
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 11 October 2018; shares registered for exchange trading on 5 October 2018.

Events of Allogene Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$956 M$1.9 B$2.9 B$3.8 B2020202120222023202420252026

World rank over time

▼ down 9,299 places since 2020
2020-01-01: #3780#3,78020202021-01-01: #3859#3,85920212022-01-07: #6446#6,44620222022-12-25: #9189#9,18920222023-07-30: #10536#10,53620232024-01-05: #11800#11,80020242026-03-08: #6912#6,91220262026-08-01: #10873#10,87320262026-10-08: #12684#12,68420262026-10-29: #13079#13,0792026

Rank in USA: #1,179 (Jan 2020) · #1,236 (Jan 2021) · #1,901 (Jan 2022) · #2,129 (Dec 2022) · #2,381 (Jul 2023) · #2,426 (Jan 2024) · #1,215 (Mar 2026) · #2,312 (Aug 2026) · #2,537 (Oct 2026) · #2,603 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.5×
Free cash flow yield
-33.2%
Net margin
—
Operating margin
—
Return on equity
-65.3%
Liabilities / assets
29.7%
Revenue growth
-80.0%
R&D / revenue
961500.0%
Revenue per employee
$0 K
Profit per employee
$-616 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-212M—FY18Fiscal year ending Dec 2019: revenue —, net income $-185M—FY19Fiscal year ending Dec 2020: revenue —, net income $-316M—FY20Fiscal year ending Dec 2021: revenue $114M, net income $-182M$114MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-340M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-327M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-258M$0MFY24Fiscal year ending Dec 2025: revenue —, net income $-191M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-209M$-191M—
Dec 2024$0M-80.0%$-273M$-258M-1287950.0%
Dec 2023$0M-37.5%$-328M$-327M-327260.0%
Dec 2022$0M-99.9%$-336M$-340M-212756.3%
Dec 2021$114M—$-180M$-182M-159.6%
Dec 2020——$-258M$-316M—
Dec 2019——$-202M$-185M—
Dec 2018——$-193M$-212M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-149M$0M$-150M$-0.87$0.00
Dec 2024$-200M$1M$-201M$-1.32$0.00
Dec 2023$-238M$2M$-239M$-2.09$0.00
Dec 2022$-221M$5M$-226M$-2.38$0.00
Dec 2021$-185M$21M$-206M$-1.34$0.00
Dec 2020$-115M$66M$-181M$-2.63$0.00
Dec 2019$-137M$51M$-188M$-1.83$0.00
Dec 2018$-45M$3M$-48M$-7.31$0.00

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-60M—Dec ’24Three months to Mar 2025: revenue —, net income $-60M—Mar ’25Three months to Jun 2025: revenue —, net income $-51M—Jun ’25Three months to Sep 2025: revenue —, net income $-41M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-39M—Dec ’25Three months to Mar 2026: revenue —, net income $-43M—Mar ’26Three months to Jun 2026: revenue $5M, net income $-43M$5MJun ’26Three months to Sep 2026: revenue —, net income $-50M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-50M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Allogene Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-209 M
Net income
$-191 M

For year ending December-2025

Balance sheet

Total assets
$416 M
Total liabilities
$123 M
Total equity
$293 M

As of December-2025

Top 100 institutional investors in Allogene Therapeutics, Inc.#

As of Sep 30, 2026
198 institutions held 303.8 M shares (about 87.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 49.6%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Allogene Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.30,927,343+780,380 (+2.59%)8.93%$49 MNov 13, 2026
2Citadel Advisors LLC24,558,325+14,470,555 (+143.45%)7.09%$39 MNov 16, 2026
3Frazier Life Sciences Management, L.P.22,446,6680 (0.00%)6.48%$36 MNov 16, 2026
4Pfizer Inc22,032,0400 (0.00%)6.36%$35 MNov 12, 2026
5State Street Corp16,326,197-2,699,629 (-14.19%)4.71%$26 MNov 12, 2026
6Primecap Management Co/ca/13,146,840+23,400 (+0.18%)3.79%$21 MNov 12, 2026
7Vanguard Capital Management LLC12,050,271-116,365 (-0.96%)3.48%$19 MNov 13, 2026
8UBS Group AG10,704,296+7,665,904 (+252.30%)3.09%$17 MNov 10, 2026
9FMR LLC10,599,559-1,409,484 (-11.74%)3.06%$17 MNov 10, 2026
10Sio Capital Management, LLC9,104,151-4,219,280 (-31.67%)2.63%$15 MNov 16, 2026
11Two Sigma Investments, LP9,012,677+1,228,329 (+15.78%)2.60%$14 MNov 16, 2026
12Marshall Wace, LLP7,973,647+2,878,239 (+56.49%)2.30%$13 MNov 13, 2026
13Geode Capital Management, LLC6,446,801-602,527 (-8.55%)1.86%$10 MNov 6, 2026
14Candriam S.C.A.5,422,820+1,086,524 (+25.06%)1.57%$9 MNov 3, 2026
15Goldman Sachs Group Inc5,330,283-818,676 (-13.31%)1.54%$9 MNov 16, 2026
16GordonMD Global Investments LP5,298,0000 (0.00%)1.53%$8 MNov 16, 2026
17Aberdeen Group plc5,259,681+257,929 (+5.16%)1.52%$8 MNov 10, 2026
18Renaissance Technologies LLC5,232,012+1,397,700 (+36.45%)1.51%$8 MNov 12, 2026
19Millennium Management LLC5,115,535+271,646 (+5.61%)1.48%$8 MNov 16, 2026
20Patient Square Capital LP4,550,000-500,000 (-9.90%)1.31%$7 MNov 10, 2026
21D. E. Shaw & Co., Inc.4,261,315-449,420 (-9.54%)1.23%$7 MNov 16, 2026
22Vanguard Portfolio Management LLC3,861,920-350,158 (-8.31%)1.11%$6 MNov 13, 2026
23HRT Financial LP3,345,358-276,221 (-7.63%)0.97%$5 MNov 13, 2026
24Morgan Stanley3,327,315-1,182,647 (-26.22%)0.96%$5 MNov 13, 2026
25RTW Investments, LP3,250,0000 (0.00%)0.94%$5 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Allogene Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Dimensional Fund Advisors LP3,202,488-36,589 (-1.13%)0.92%$5 MNov 4, 2026
27Wildcat Capital Management, LLC2,920,7870 (0.00%)0.84%$5 MOct 28, 2026
28Woodline Partners LP2,810,624-1,690,000 (-37.55%)0.81%$4 MNov 16, 2026
29Northern Trust Corp2,809,197-146,085 (-4.94%)0.81%$4 MNov 16, 2026
30Ameriprise Financial Inc2,613,430+2,143,564 (+456.21%)0.75%$4 MNov 16, 2026
31Charles Schwab Investment Management Inc2,370,314+95,951 (+4.22%)0.68%$4 MNov 16, 2026
32Acadian Asset Management LLC2,223,697+1,905,331 (+598.47%)0.64%$4 MNov 9, 2026
33Walleye Capital LLC2,205,649-1,062,363 (-32.51%)0.64%$4 MNov 13, 2026
34Bank Of America Corp /de/2,007,897-1,179,423 (-37.00%)0.58%$3 MNov 16, 2026
35DAFNA Capital Management LLC2,000,0000 (0.00%)0.58%$3 MNov 16, 2026
36Vanguard Fiduciary Trust Co1,804,543-33,801 (-1.84%)0.52%$3 MNov 13, 2026
37Boxer Capital Management, LLC1,500,0000 (0.00%)0.43%$2 MNov 16, 2026
38Price T Rowe Associates Inc /MD/1,449,861-3,189,422 (-68.75%)0.42%$2 MNov 16, 2026
39Jpmorgan Chase & Co1,420,277-18,157 (-1.26%)0.41%$2 MNov 12, 2026
40Qube Research & Technologies Ltd1,178,377New0.34%$2 MNov 13, 2026
41Connor, Clark & Lunn Investment Management Ltd.1,117,103+794,276 (+246.04%)0.32%$2 MNov 10, 2026
42Raiffeisen Bank International AG1,100,0000 (0.00%)0.32%$2 MOct 28, 2026
43Hennion & Walsh Asset Management, Inc.1,039,328+316,400 (+43.77%)0.30%$2 MOct 13, 2026
44Ghisallo Capital Management LLC1,000,000-2,000,000 (-66.67%)0.29%$2 MNov 16, 2026
45Invesco Ltd.843,967+71,181 (+9.21%)0.24%$1 MNov 12, 2026
46Bank of New York Mellon Corp749,988+22,806 (+3.14%)0.22%$1 MNov 5, 2026
47Raymond James Financial Inc652,543-26,429 (-3.89%)0.19%$1 MNov 12, 2026
48Nuveen, LLC627,956+3,308 (+0.53%)0.18%$1 MNov 10, 2026
49Mitsubishi UFJ Asset Management Co., Ltd.546,210-979 (-0.18%)0.16%$1 MNov 5, 2026
50Gsa Capital Partners LLP542,723+257,133 (+90.04%)0.16%$1 MNov 16, 2026
51Man Group plc518,882-183,019 (-26.07%)0.15%$1 MNov 16, 2026
52Franklin Templeton Inc483,157New0.14%$1 MNov 12, 2026
53Alps Advisors Inc454,472+104,169 (+29.74%)0.13%$1 MNov 3, 2026
54Creative Planning453,806+27,369 (+6.42%)0.13%$1 MNov 2, 2026
55Rafferty Asset Management, LLC401,856+64,321 (+19.06%)0.12%$1 MNov 13, 2026
56BIT Capital GmbH388,000+158,000 (+68.70%)0.11%$1 MNov 13, 2026
57Squarepoint Ops LLC376,940+135,416 (+56.07%)0.11%$1 MNov 9, 2026
58Point72 Asset Management, L.P.368,461New0.11%$1 MNov 16, 2026
59Rhumbline Advisers335,212+25,471 (+8.22%)0.10%$1 MNov 10, 2026
60Voleon Capital Management LP309,220-176,401 (-36.32%)0.09%$0 MNov 16, 2026
61Citigroup Inc308,864-206,635 (-40.08%)0.09%$0 MNov 4, 2026
62Harold Davidson & Associates Inc.281,434-88 (-0.03%)0.08%$0 MOct 29, 2026
63Empirical Financial Services, LLC d.b.a. Empirical Wealth Management279,259New0.08%$0 MOct 27, 2026
64AQR Capital Management LLC261,324-1,744,964 (-86.97%)0.08%$0 MNov 16, 2026
65Ieq Capital, LLC258,440-321,931 (-55.47%)0.07%$0 MNov 10, 2026
66HSBC Holdings PLC248,329-11,418 (-4.40%)0.07%$0 MNov 16, 2026
67Deutsche Bank AG\248,091-33,858 (-12.01%)0.07%$0 MNov 6, 2026
68Susquehanna International Group, LLP231,290+137,649 (+147.00%)0.07%$0 MNov 16, 2026
69Barclays PLC228,375+8,657 (+3.94%)0.07%$0 MNov 6, 2026
70Alliancebernstein L.P.225,8780 (0.00%)0.07%$0 MNov 16, 2026
71LPL Financial LLC220,600-70 (-0.03%)0.06%$0 MNov 6, 2026
72Cerity Partners LLC213,338-116,952 (-35.41%)0.06%$0 MNov 13, 2026
73Canada Pension Plan Investment Board204,500+89,000 (+77.06%)0.06%$0 MNov 16, 2026
74XTX Topco Ltd203,752+172,829 (+558.90%)0.06%$0 MNov 16, 2026
75American Century Companies Inc194,180-13,224 (-6.38%)0.06%$0 MNov 12, 2026
76Mason & Associates Inc174,761New0.05%$0 MNov 16, 2026
77Manufacturers Life Insurance Company, The174,453-251,821 (-59.07%)0.05%$0 MNov 13, 2026
78OpenArc Corporate Advisory, LLC174,2580 (0.00%)0.05%$0 MOct 21, 2026
79BFC Planning, Inc.173,000New0.05%$0 MNov 13, 2026
80Quadrature Capital Ltd171,735-38,758 (-18.41%)0.05%$0 MNov 13, 2026
81Virtus Investment Advisers, LLC167,018-5,191 (-3.01%)0.05%$0 MNov 12, 2026
82Partners Capital Investment Group, LLP161,5970 (0.00%)0.05%$0 MNov 16, 2026
83MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.159,832-1,606 (-0.99%)0.05%$0 MNov 16, 2026
84TD Asset Management Inc154,680-307,400 (-66.53%)0.04%$0 MNov 13, 2026
85Indivisible Partners147,000New0.04%$0 MOct 26, 2026
86Nomura Asset Management International Inc.146,7790 (0.00%)0.04%$0 MNov 16, 2026
87Royal Bank Of Canada145,390-41,037 (-22.01%)0.04%$0 MNov 16, 2026
88Profund Advisors LLC141,379-28,319 (-16.69%)0.04%$0 MOct 29, 2026
89Choreo, LLC137,212+12,150 (+9.72%)0.04%$0 MOct 28, 2026
90CANADA LIFE ASSURANCE Co131,320+55,371 (+72.91%)0.04%$0 MNov 13, 2026
91MetLife Investment Management, LLC131,119-25,056 (-16.04%)0.04%$0 MNov 16, 2026
92Brevan Howard Capital Management LP125,630+86,612 (+221.98%)0.04%$0 MNov 16, 2026
93Russell Investments Group, Ltd.123,601-314,808 (-71.81%)0.04%$0 MNov 6, 2026
94Bridgeway Capital Management, LLC122,895-127,105 (-50.84%)0.04%$0 MNov 16, 2026
95Empowered Funds, LLC122,895New0.04%$0 MNov 13, 2026
96SEI Investments Co115,919+67,599 (+139.90%)0.03%$0 MNov 10, 2026
97Smartleaf Asset Management LLC115,690-22,184 (-16.09%)0.03%$0 MNov 10, 2026
98Vanguard Global Advisers, LLC101,051-114,134 (-53.04%)0.03%$0 MNov 13, 2026
99BNP Paribas Financial Markets98,750+41,991 (+73.98%)0.03%$0 MNov 12, 2026
100Engineers Gate Manager LP89,389-9,122 (-9.26%)0.03%$0 MNov 16, 2026

All 198 institutional investors, with who bought and sold →

Mutual funds holding Allogene Therapeutics, Inc.#

136 funds hold shares worth $201 M (about 28.1% of the company). Since their previous reports 91 added shares and 22 sold, buying $95 M net.
Mutual funds holding Allogene Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.12.14 M$25 M3.5%0.24%+133%Jun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC9.55 M$21 M2.8%0.39%+581%May 31, 2026
🇺🇸 Vanguard Capital Opportunity FundPRIMECAP Management Company9.39 M$20 M2.7%0.06%+75%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.8.67 M$18 M2.5%<0.01%+78%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors6.92 M$14 M2.0%0.02%+80%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.3.44 M$7 M0.99%0.06%−10%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.3.22 M$7 M0.93%<0.01%+71%Jun 30, 2026
🇺🇸 PRIMECAP Odyssey Aggressive Growth FundPRIMECAP Management Company3.48 M$7 M1.0%0.09%+3.0%Jul 31, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.2.73 M$6 M0.79%0.82%+87%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC2.91 M$5 M0.84%0.02%+88%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors2.48 M$5 M0.72%0.04%+83%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors1.80 M$4 M0.52%0.04%+57%Jun 30, 2026
🇺🇸 abrdn Healthcare Investorsabrdn Inc.1.77 M$4 M0.51%0.27%newJun 30, 2026
🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC1.80 M$3 M0.52%0.14%newJul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC1.44 M$3 M0.42%0.06%newMay 29, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC1.44 M$3 M0.42%0.05%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC1.32 M$3 M0.38%<0.01%+52%May 31, 2026
🇺🇸 State Street SPDR S&P Kensho New Economies Composite ETFSSGA Funds Management, Inc.1.31 M$3 M0.38%0.10%newJun 30, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC1.21 M$3 M0.35%0.04%no changeMay 29, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.1.21 M$3 M0.35%0.01%+53%May 31, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.1.16 M$2 M0.33%0.08%newJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP1.03 M$2 M0.30%0.01%+17%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.799,026$2 M0.23%<0.01%+4.6%May 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.743,762$2 M0.21%<0.01%+64%May 31, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.631,204$1 M0.18%0.19%newJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP665,641$1 M0.19%<0.01%+408%Jul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP665,494$1 M0.19%0.02%+224%Jul 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.645,365$1 M0.19%0.02%+89%Jul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC588,543$1 M0.17%0.04%+6.3%Jul 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.496,849$1 M0.14%0.06%newMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC476,775$1 M0.14%<0.01%+46%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC496,148$1 M0.14%0.02%+89%Jun 30, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I469,495$1 M0.14%0.08%newMay 31, 2026
🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors476,459$1 M0.14%0.02%newJul 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC407,995$1 M0.12%<0.01%−59%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC386,508$1 M0.11%<0.01%+66%May 31, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC412,615$1 M0.12%0.16%+36%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC372,025$1 M0.11%0.04%+92%Jun 30, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors353,956$1 M0.10%<0.01%+2.4%Jun 30, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC344,966$1 M0.10%0.07%−1.1%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC352,649$1 M0.10%0.02%+107%Jul 31, 2026
🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS304,265$1 M0.09%0.14%+117%Jun 30, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.295,178$1 M0.09%0.05%−5.7%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC288,539$1 M0.08%0.02%+65%Jun 30, 2026
🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS277,844$1 M0.08%0.26%+130%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC250,000$1 M0.07%0.35%no changeJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.243,268$1 M0.07%0.07%no changeJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP241,276$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust204,346$0 M0.06%0.02%newMay 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC219,943$0 M0.06%<0.01%+334%Jul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation191,000$0 M0.06%0.02%+104%Jun 30, 2026
🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC182,977$0 M0.05%0.04%−14%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC167,572$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC165,591$0 M0.05%0.05%+23%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds165,491$0 M0.05%0.04%newJun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.149,554$0 M0.04%<0.01%+13%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.149,004$0 M0.04%<0.01%+67%Jun 30, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company146,779$0 M0.04%0.04%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC162,243$0 M0.05%<0.01%+89%Jul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC140,441$0 M0.04%0.02%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.137,154$0 M0.04%0.02%+78%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.148,999$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.128,181$0 M0.04%<0.01%+83%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.119,752$0 M0.03%0.02%+7.1%May 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC126,787$0 M0.04%0.02%+87%Jul 31, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC104,283$0 M0.03%0.04%−1.1%Jun 30, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC94,053$0 M0.03%0.11%—Apr 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC103,519$0 M0.03%<0.01%+74%Jul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC88,543$0 M0.03%0.02%+76%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC87,072$0 M0.03%0.02%+153%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.81,731$0 M0.02%<0.01%+59%Jun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors78,774$0 M0.02%<0.01%+21%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC76,123$0 M0.02%0.02%+103%Jun 30, 2026
🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC73,908$0 M0.02%0.13%—Jun 30, 2026
🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC72,609$0 M0.02%0.05%−14%Jun 30, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC72,554$0 M0.02%0.04%−1.1%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC72,032$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC70,293$0 M0.02%0.06%−44%Jun 30, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC68,948$0 M0.02%0.04%newJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company62,314$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP71,758$0 M0.02%<0.01%+13%Jul 31, 2026
🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company60,126$0 M0.02%0.05%newMay 31, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC59,892$0 M0.02%0.07%−35%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS58,841$0 M0.02%0.02%+98%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC54,998$0 M0.02%0.02%+94%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC49,800$0 M0.01%<0.01%+5.1%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC47,676$0 M0.01%0.01%+18%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC47,322$0 M0.01%<0.01%+115%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.41,656$0 M0.01%0.02%+92%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC41,487$0 M0.01%0.02%+73%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.40,481$0 M0.01%0.02%+106%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC43,507$0 M0.01%0.02%+75%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC35,848$0 M0.01%0.02%+70%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC32,767$0 M<0.01%<0.01%−23%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC31,512$0 M<0.01%0.02%+95%Jun 30, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC28,341$0 M<0.01%0.04%−11%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC31,081$0 M<0.01%0.02%+84%Jul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.29,521$0 M<0.01%<0.01%+72%Jul 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors24,956$0 M<0.01%<0.01%−0.8%Jun 30, 2026
🇺🇸 EQ/Common Stock Index PortfolioEquitable Investment Management Group, LLC24,600$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Allogene Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$668 K
14 sales, 6 insiders
Net, 12 months
-$668 K
open market only
Insiders on file
25
since
$5.0 M-$337 K$0Dec 2023: bought $0 (0 trades), sold $50 K (1 trades)Dec 23Jan 2024: bought $684 (1 trades), sold $0 (0 trades)May 2024: bought $5.0 M (1 trades), sold $26 K (1 trades)Jun 2024: bought $0 (0 trades), sold $43 K (1 trades)JunDec 2024: bought $0 (0 trades), sold $40 K (2 trades)Jan 2025: bought $0 (0 trades), sold $48 K (1 trades)Feb 2025: bought $0 (0 trades), sold $185 K (6 trades)FebMar 2025: bought $0 (0 trades), sold $102 K (2 trades)Apr 2025: bought $0 (0 trades), sold $14 K (1 trades)Jun 2025: bought $0 (0 trades), sold $52 K (1 trades)JunOct 2025: bought $0 (0 trades), sold $46 K (1 trades)Nov 2025: bought $0 (0 trades), sold $959 (1 trades)Jan 2026: bought $0 (0 trades), sold $41 K (1 trades)Jan 26Feb 2026: bought $0 (0 trades), sold $337 K (6 trades)Mar 2026: bought $0 (0 trades), sold $156 K (4 trades)Apr 2026: bought $0 (0 trades), sold $22 K (1 trades)AprAug 2026: bought $0 (0 trades), sold $63 K (1 trades)Oct 2026: bought $0 (0 trades), sold $49 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Allogene Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Geoffrey M. ParkerCHIEF FINANCIAL OFFICERSell-36,342$1.340$49 K1.05 MForm 4
filed Earl Martin DouglasSVP, General CounselSell-29,697$2.120$63 K488,267Form 4
filed Joshua A. KazamDirectorOption exercise+47,700——398,463Form 4
filed Annie YoshiyamaSVP, FinanceSell-9,586$2.310$22 K124,517Form 4
filed Benjamin Machinas BeneskiSVP, Chief Technical OfficerSell-2,867$2.500$7 K195,338Form 4
filed Benjamin Machinas BeneskiSVP, Chief Technical OfficerSell-4,835$2.470$12 K198,205Form 4
filed David D. ChangPresident and CEO, DirectorSell-47,763$2.470$118 K5.15 MForm 4
filed Benjamin Machinas BeneskiSVP, Chief Technical OfficerSell-7,132$2.600$19 K203,040Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Allogene Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
51.3 M
22.4% of shares · 6.2 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-5.25 reverse split

Trading halts

  • 2026-04-13 11:25 UTC, code T3, resumed 12:00 UTC
  • 2025-02-19 14:31 UTC, code LUDP, resumed 14:41 UTC

Fails to deliver

  • : 875,974 shares at $1.30
  • : 189,481 shares at $1.23
  • : 666,195 shares at $1.21
  • : 9,223 shares at $1.25
  • : 1 shares at $1.31

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Allogene Therapeutics, Inc. scorecard#

Passes 3 of the 14 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-33.2%Free cash flow is -33.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.87 vs -1.32Diluted EPS -0.87 in fiscal 2025 against -1.32 the year before (report's currency).
    • ✓Net income higher than five years earlier-$191 M-$191 M in fiscal 2025 against -$316 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$191 MNet income -$191 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-53.4%-53.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities7.9×Current ratio 7.93 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 3
    • ✗Pays a dividendNoNo dividends in fiscal 2025.
    • ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2025.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year13.2%Diluted shares up 13.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Allogene Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Allogene Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue00.00.10.2r114r00—
Research and development150192243256220193145152
General and administrative5765727974655741
Operating expenses209273328336294258202193
Operating income−209−273−328−336r−180r−258−202−193
Interest expense and finance costs1.10.20——003.4
Share of profit of associates0−1.7−11—————
Other non-operating income (expense)18160.5−4.9r−1.9r−58r17−19
Income before tax−191−257−327—−257−250−185−212
Income tax00.40000−0.3−0.1
Net income including minority interests−191−258−327−340r−182r−316r−185−212
Net income attributable to shareholders−191−258−327−340r−182r−316r−185−212
Earnings per share, basic-0.87-1.32-2.09-2.38r-1.34r-2.63r-1.83-7.31
Earnings per share, diluted-0.87-1.32-2.09-2.38r-1.34r-2.63r-1.83-7.31
Shares, weighted average (basic)221195157143136120101—
Shares, weighted average (diluted)22119515714313612010129
Dividends per share0.000.000.000.000.000.000.000.00
Balance sheet
Cash and cash equivalents5275836217318317592
Short-term investments199217366455284645355367
Other current assets7.51110121417148.6
Current assets258303459529471845545468
Property, plant and equipment738699113123119568.6
Right-of-use (leased) assets4045648458414433
Other intangible assets—————00.20.8
Long-term investments——————58262
Total assets416549643822r1,051r1,228718774
Accounts payable4.35.45.91410109.312
Current liabilities33363754r48r943329
Lease liabilities (non-current)7583889570515134
Total liabilities123127131155r126r1488971
Retained earnings−2,011−1,820−1,562−1,235r−895r−713r−396−212
Shareholders' equity293422512667r925r1,013r629703
Total liabilities and equity416549643822r1,051r1,228718774
Shares outstanding229212169144143140124121
Cash-flow statement
Depreciation and amortization121414r14117.44.61.0
Share-based compensation3852668481654619
Cash from operating activities−149−200−238−221−185−115−137−45
Capital expenditure−0.4−0.7−1.5−5.2−21−66−51−3.2
Cash from investing activities9676163106164−505164−633
Shares issued——9100596r0r344
Cash from financing activities30117963.01263459771
Change in cash−24−7.921−111−9.2138694
Report10-K10-K10-K10-K10-K10-K/A10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Allogene Therapeutics, Inc. sells: revenue by product line, fiscal 2024#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable$0 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2024

Executive pay at Allogene Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$6.1 M
Dr. Chang
Other top executives, average
$2.3 M
the CEO earned 2.7× this
$100 invested is now
$22
Allogene Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Chang$6.1 M$1.9 M$2.3 M$22
2024Zachary Roberts$4.5 M$872 K$2.0 M$34
2023Zachary Roberts$14.1 M$1.3 M$7.0 M$51

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Allogene Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 4 · Material agreement 3 · Agreement ended 1 · Shareholder vote 3 · Results announced 11

Allogene Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementAgreement endedResults announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Material agreement8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Allogene Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2018$412 MNo. 1$250 million to $1 billion23equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Allogene Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $225 K a year.

Certified, FY2026
1
#1,799 among companies on value.today
Worker positions
1
Median wage offered
$225 K
a year, full-time
Applications filed
1
Allogene Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior Manager, Quality and Regulatory SystemsComputer and Information Systems Managers1$225 K

Where: South San Francisco, CA 1

Allogene Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$225 K1
FY202411$129 K1
FY202333$177 K3
FY202266$157 K6
FY202122$129 K2
FY202022$160 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Allogene Therapeutics, Inc.

Layoffs at Allogene Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2024
Latest
—
2024-01-03
Allogene Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
Allogene Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
22% of workforceRestructuring planSEC 8-K“On January 4, 2024, the Company’s Board of Directors approved a reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’…”Filing

Source: State WARN notices and SEC 8-K item 2.05

Discuss Allogene Therapeutics, Inc.#

3 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 5 November 2026automatic update · Nov 5, 2026

    Allogene Therapeutics, Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $50 million.

  • Insider trading in October 2026automatic update · Oct 31, 2026

    Directors and officers of Allogene Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $48,698 in 1 trade. Awards, option exercises and shares withheld for tax are not counted.

  • Mutual funds: 136 funds hold $201 millionautomatic update · Jul 31, 2026

    136 mutual funds in 1 country hold shares of Allogene Therapeutics, Inc. worth $201 million, about 28.1% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 91 funds added shares and 22 sold; on balance they bought $95 million. Share splits are not counted as trading.

How Allogene Therapeutics, Inc. compares in Biotechnology

  • Market cap$450 M · higher than 56% of 726
  • Revenue$0 M · higher than 0% of 647
  • Revenue growth-80.0% · higher than 6% of 438
  • Price / book1.5× · lower than 66% of 534
  • FCF yield-33.2% · higher than 33% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Allogene Therapeutics, Inc.🇺🇸$450 M——-80.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, value.today research, SEC filing.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Allogene Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Allogene Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Allogene Therapeutics, Inc.? Suggest a correction